Monte Rosa Therapeutics, Inc. (GLUE) vs SI-BONE, Inc. (SIBN)
A side-by-side comparison of Monte Rosa Therapeutics, Inc. and SI-BONE, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GLUE
Monte Rosa Therapeutics, Inc.
$9.87HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SIBN
SI-BONE, Inc.
$19.55HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — GLUE vs SIBN
growth of $100 · dividends reinvested · last 5yGLUE -51.5% (-13.5%/yr)SIBN -38.9% (-9.4%/yr)SIBN compounded faster over this window
GLUE SIBN
GLUE vs SIBN: by the numbers
- •SIBN is the larger company ($867M vs $834M market cap).
- •Both run net losses; SIBN's is the smaller (-6.85% vs -560.85% net margin).
Metrics side by side
Valuation
| Metric | GLUE | SIBN |
|---|---|---|
| P/S ratio | 29.03 | 4.06 |
| P/B ratio | 1.71 | 4.75 |
Profitability
| Metric | GLUE | SIBN |
|---|---|---|
| Gross margin | 92.94% | 79.53% |
| Operating margin | -43.83% | -8.31% |
| Net margin | -560.85% | -6.85% |
| ROE | -33.06% | -8.03% |
| ROIC | -28.69% | -7.88% |
Growth (annualized)
| Metric | GLUE | SIBN |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 20.20% |
| Total return CAGR (5Y) | -12.32% | -1.46% |
Frequently asked
- How have GLUE and SIBN total returns compared?
- Over the past 5 years, GLUE delivered -12.32% and SIBN delivered -1.46% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Monte Rosa Therapeutics ROESI-BONE ROEMonte Rosa Therapeutics operating marginSI-BONE operating marginMonte Rosa Therapeutics revenue growthSI-BONE revenue growthMonte Rosa Therapeutics free cash flowSI-BONE free cash flow
Monte Rosa Therapeutics & SI-BONE appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.